Literature DB >> 2769496

Erythrocyte membrane lipid peroxidation before and after vitamin E supplementation in children with cholestasis.

R Lubrano1, T Frediani, G Citti, E Cardi, O Mannarino, M Elli, F Cozzi, O Giardini.   

Abstract

In 10 children with chronic cholestasis and without neurologic signs, we evaluated lipid peroxidation and vitamin E levels in serum and in the erythrocytes before and after a therapeutic trial with alpha-tocopherol. We also studied the effects of vitamin E administration on hematocrit and hemoglobin values and on reticulocyte and erythrocyte counts. Plasma and erythrocyte malonyldialdehyde (MDA) values were significantly higher compared with normal control values, whereas plasma and erythrocyte tocopherol measurements were lower. Oral administration of high doses of vitamin E (300 mg/day for 15 days) resulted in lower serum MDA levels, whereas serum vitamin levels did not change significantly. In erythrocytes, the MDA decreased but not to control levels, and vitamin E increased but to lower values than normal. Hematologic values also improved. We conclude that longer treatment might be necessary to completely reverse the oxidative damage associated with vitamin E deficiency in children with cholestasis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2769496     DOI: 10.1016/s0022-3476(89)80835-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  2 in total

1.  Deuterated Linoleic Acid Attenuates the RBC Storage Lesion in a Mouse Model of Poor RBC Storage.

Authors:  Christopher Y Kim; Hannah Johnson; Sandy Peltier; Steven L Spitalnik; Eldad A Hod; Richard O Francis; Krystalyn E Hudson; Elizabeth F Stone; Dominique E Gordy; Xiaoyun Fu; James C Zimring; Pascal Amireault; Paul W Buehler; Robert B Wilson; Angelo D'Alessandro; Mikhail S Shchepinov; Tiffany Thomas
Journal:  Front Physiol       Date:  2022-04-26       Impact factor: 4.755

Review 2.  Dosage and formulation issues: oral vitamin E therapy in children.

Authors:  Tone Westergren; Betty Kalikstad
Journal:  Eur J Clin Pharmacol       Date:  2009-10-13       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.